Alpha-1-Antitrypsin Enhances Fat Graft Survival in a Murine Model

Area of Science:

• Regenerative Medicine
• Tissue Engineering
• Immunology

Background:

• Fat grafting is a common procedure for volume restoration and tissue enhancement.
• Poor long-term graft survival and unpredictable outcomes remain significant challenges.
• Alpha-1-antitrypsin (AAT) is explored for its potential to modulate inflammation and improve vascularity.

Purpose of the Study:

• To investigate the efficacy of Alpha-1-antitrypsin (AAT) in improving fat graft survival and quality.
• To determine the impact of AAT on graft vascularity, inflammation, and adipogenesis.
• To assess the potential of AAT as an adjunct therapy for fat grafting.

Main Methods:

• Fat grafts were administered to mice with or without AAT (400 µg/graft) on days 0 and 3.
• Graft volume was assessed using micro-magnetic resonance imaging.
• Explants were analyzed for viability, histology, gene expression (adiponectin, IL-1β), and metabolic function (XTT assay).

Main Results:

• AAT-treated grafts showed significantly higher volume retention (70.06% vs. 34.54%) after 90 days.
• Increased vascularity (1.94/mm² vs. 0.33/mm²) and adiponectin levels were observed in AAT grafts.
• AAT treatment led to reduced late-stage IL-1β expression and enhanced metabolic function and adipogenesis.

Conclusions:

• Early administration of Alpha-1-antitrypsin (AAT) significantly enhances fat graft survival and tissue quality.
• AAT likely improves outcomes by accelerating inflammatory resolution and promoting graft vascularization.
• AAT demonstrates potential as a safe and effective adjunct therapy to improve fat grafting predictability.